Free Trial

Top Growth Stocks To Research - October 13th

Prologis logo with Finance background

Key Points

  • Prologis, Hamilton Lane, and Ascendis Pharma A/S are highlighted as the top growth stocks to research, each showcasing strong trading volume and significant market potential.
  • Prologis is the leader in logistics real estate with extensive property holdings and investments across 19 countries.
  • Hamilton Lane specializes in private equity investments across various sectors, while Ascendis Pharma focuses on developing biopharmaceutical therapies for unmet medical needs.
  • Five stocks to consider instead of Prologis.

Prologis, Hamilton Lane, and Ascendis Pharma A/S are the three Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to grow revenue and earnings faster than the broader market, typically reinvesting profits into expansion rather than paying dividends. Investors buy them for capital appreciation, but they often carry higher valuations and greater volatility, making them riskier if growth falls short of expectations. These companies had the highest dollar trading volume of any Growth stocks within the last several days.

Prologis (PLD)

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.

Read Our Latest Research Report on PLD

Hamilton Lane (HLNE)

Hamilton Lane Incorporated is a private equity firm specializing in early venture, emerging growth, turnaround, middle market, mature, mid-venture, bridge, buyout, distressed/vulture, loan, mezzanine in growth capital companies. It prefers to invest in energy, industrials, consumer discretionary, health care, real estate, information technology, utilities, and consumer services.

Read Our Latest Research Report on HLNE

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Read Our Latest Research Report on ASND

Read More

Should You Invest $1,000 in Prologis Right Now?

Before you consider Prologis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prologis wasn't on the list.

While Prologis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.